A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.
- DOI
- 10.1002/cam4.573
- Published
- 2016-01-25
- Container
- Cancer Med
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/cam4.573,
title = {A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.},
author = {De Cock E and Pivot X and Hauser N and Verma S and Kritikou P and Millar D and Knoop A.},
year = {2016},
journal = {Cancer Med},
doi = {10.1002/cam4.573},
url = {https://doi.org/10.1002/cam4.573}
}RIS
TY - JOUR TI - A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. AU - De Cock E AU - Pivot X AU - Hauser N AU - Verma S AU - Kritikou P AU - Millar D AU - Knoop A. PY - 2016 JO - Cancer Med DO - 10.1002/cam4.573 UR - https://doi.org/10.1002/cam4.573 ER -
APA
E, D. C., X, P., N, H., S, V., P, K., D, M., & A., K. (2016). A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.. Cancer Med. https://doi.org/10.1002/cam4.573
Source records
- europe-pmc · retrieved 2026-09-27T11:19:41.255Z